Multiple genetic aberrations in the regulation of BCL6, including in acetyltransferase genes, occur in clinically aggressive B-cell lymphomas and lead to higher expression levels and activity of this transcriptional repressor. BCL6 is, therefore, an attractive target for therapy in aggressive lymphomas. In this study romidepsin, a potent histone deacetylase inhibitor (HDACi), induced apoptosis and cell cycle arrest in Burkitt and diffuse large B-cell lymphoma cell lines, which are model cells for studying the mechanism of action of BCL6. Romidepsin caused BCL6 acetylation at early timepoints inhibiting its function, while at later timepoints BCL6 expression was reduced and target gene expression increased due to chromatin modification. MYC contributes to poor prognosis in aggressive lymphoma. MYC function is reduced by inhibition of chromatin readers of the bromodomain and extra-terminal repeat (BET) family, which includes BRD4. The novel combination of romidepsin and JQ1, a BRD4 inhibitor was investigated and showed synergy. Collectively we suggest that the combination of HDACi and BRD4i should be pursued in further pre-clinical testing.
leading to increased BCL6 expression have been described 7, 8 and BCL6 is also involved in chromosomal translocations in ~25% of DLBCL 9 . Thus, modulation of BCL6 expression could be a potential target for therapy in lymphomas. Indeed, BCL6 inhibition using specific inhibitors was able to produce apoptosis and cell cycle arrest of these cells 10, 11 suggesting that BCL6 may be a promising therapeutic target in lymphoma 12, 13 .
We and others, have recently shown that epigenetic mechanisms are involved in BCL6 regulation [14] [15] [16] . Histone deacetylase inhibitors (HDACi) are a novel class of antitumor agents that have shown very promising results for the treatment of a number of hematologic malignancies 17, 18 . Regulation of the reversible acetylation status of an increasing number of non-histone proteins, many of them being proto-oncogenes, allows to modulate a number of essential cellular processes such as protein interactions, protein stability, apoptosis, cell proliferation and cell survival 19 . Particularly, HDAC inhibitors have been shown to inhibit BCL6 function by inducing its acetylation, which leads to de-repression of its target genes 20 . Romidepsin is an HDACi with high inhibitory activity for class I histone deacetylases that is approved by the FDA for the treatment of cutaneous T-cell lymphoma or refractory/ relapsed peripheral T-cell lymphoma 21, 22 . HDACi synergize with other agents including hypomethylating agents in pre-clinical models of DLBCL 23 .
MYC translocations occur in 10-15% of DLBCL 1 . High expression of MYC, independent of the presence of chromosomal translocations involving MYC, is associated with poor clinical outcome in B-cell lymphoma 24, 25 . There is interest in the bromodomain and extra-terminal (BET) family member BRD4, which recognizes acetylated histones and plays an essential role in the regulation of MYC expression 26 . BRD4 (bromodomain-containing protein-4) inhibitors 27 such as JQ1 are able to cause MYC oncogene downregulation in a variety of human cancers, including leukemia and lymphoma 28 . BET inhibitors are currently being used in clinical trials 29 .
Promising data on combining HDACi with BRD4 inhibitors has been reported 18 . This combination has a specific rationale in DLBCL and BL as it potentially targets MYC in poor prognosis disease. Thus, the aim of this study was to investigate the effects of romidepsin alone or in combination with the BRD4 inhibitor, JQ1, in the treatment of aggressive lymphomas, and to identify the molecular mechanisms involved in its effects.
Results
Romidepsin promotes apoptosis in cells from agressive lymphomas. As a first approach, we measured cell proliferation (based on metabolic activity) upon romidepsin treatment to establish a dose-response assessment and to analyze the effect of the HDACi on proliferation at different time points (Fig. 1a ). Romidepsin was tested in different types of aggressive B-cell lymphoma cell lines: three Burkitt lymphoma cell lines (Raji, DG75 and Ramos), one GC-DLBCL (Toledo) and one ABC-DLBCL (Ly03) (see Supplementary Table S1 ).
At 48 h, Raji and DG75 cells showed little (10-20%) reduction of metabolic activity (Fig. 1a) , even with the highest doses tested (10 nM). Ramos cells were the most sensitive, showing a metabolic reduction 50% after treatment with romidepsin (5 nM) while both Toledo and Ly03, showed intermediate sensitivity. Very high doses of romidepsin inhibit almost completely the proliferation of all the lymphoma cell lines studied (not shown). Given that with 1 nM concentration did not show any significant effect on the studied cell lines and 10 nM treatment resulted in cell death for the most sensitive cell lines, we chose 2 nM and 5 nM as optimal concentrations for further experiments.
To evaluate the effects of romidepsin on apoptosis, Annexin V binding was determined ( Fig. 1b ). No significant cell death was observed for the metabolically less-sensitive cell lines Raji and DG75, while the sensitive cell lines Ramos, Toledo and Ly03, showed significant apoptosis induction after treatment with romidepsin (5 nM) ( Fig. 1b ). The apoptotic effects of this drug were verified using the PARP1 cleavage assay. Cleaved PARP1 was found in the high and moderate sensitive cell lines (Ramos, Toledo and Ly03) but not in the less sensitive ones (Raji and DG75) ( Fig. 1c ).
We next examined the effect of romidepsin on expression of some BCL2 family members (Fig. 2) . The intrinsic apoptotic pathway can be primarily activated by chemotherapeutic drugs and various studies support its role in HDACi mediated cell death 30 . In agreement with previous reports, BCL2 expression was neither observed in Ramos or DG75 in basal conditions 31, 32 or upon treatment with romidepsin. There was little change in the level of BCL2 in Raji and Toledo while there was suppression in Ly03 ( Fig. 2a ), confirming previous results indicating that romidepsin is able to induce apoptosis despite BCL2 expression 33 . Other pro-survival proteins were investigated: BCL-xL levels were high in basal conditions and were reduced upon treatment in the sensitive cell lines with the exception of Ly03 ( Fig. 2b ), suggesting that downregulation of BCL-xL might be mediating romidepsin apoptotic effect on germinal center derived cells. Transient expression or little change was observed in MCL1 levels with romidepsin ( Fig. 2c ). Interestingly, the pro-apoptotic protein BIM ( Fig. 2d ), showed some increase with romidepsin in DLBCL cell lines (Toledo and Ly03), which was in agreement with the PARP1 cleavage pattern detected with romidepsin treatment.
Altogether, these results demonstrate that romidepsin can repress metabolic activity and induce variable levels of apoptosis associated with changes in expression of BCL2 family proteins that might be different upon the different subtypes of lymphomas.
Romidepsin induces cell cycle arrest accompanied with p21 and p27 up-regulation. Romidepsin
has previously been shown to induce cell cycle arrest in cells from different tissues 22 . Based on this information, we aimed to analyze the cell cycle in cell lines with different responses to the HDACi (Fig. 3a) . The fraction of cells in the sub-G 0 /G 1 phase upon 48 h of romidepsin treatment, corresponding to subdiploid dead cells (inset in Fig. 3a) , is in agreement with the apoptosis observed in the sensitive Ramos, Toledo and Ly03 cells ( Fig. 1) . In Raji and DG75, the percentage of cells in sub-G 0 /G 1 did not change upon romidepsin (inset in Fig. 3a) , however a significant accumulation of cells in G 0 /G 1 was found (main graph in Fig. 3a ) indicating that even in those less-sensitive cells, a certain antiproliferative effect was observed. For Ramos and Ly03 the accumulation in G 0 /G 1 was smaller but still statistically significant. The cell population distribution in Toledo cell line was not substantially affected (main graph in Fig. 3a ).
Given the effects of HDACi on cell cycle arrest, we wonder whether the cell cycle inhibitors p27 Kip1 (p27) and p21 Cip1 (p21) were involved as has been reported for other HDACi 34 . We observed an increase of p21 protein levels in DG75 and Ramos cells treated with romidepsin ( Fig. 3b ). The increase in p21 in Toledo cells was no so prominent, probably reflecting the lack of cell cycle arrest in these cells. Additionally, levels of p27 were increased in Raji, DG75, Ramos and Ly03 in the presence of romidepsin ( Fig. 3b ). There is, therefore, no clear agreement between protein levels of p21 and p27 and the clear block in G 1 phase that the drug provokes across all these cell lines ( Fig. 3a ). Overall, romidepsin induces cell cycle arrest together with increase in p21 and p27 expression in Ramos, the most sensitive cell line.
Romidepsin provokes BCL6 downregulation and triggers plasma cell differentiation. BCL6 is a
transcriptional repressor and one of the "master regulators" that controls the exit of the B-cells from the germinal centers in order to differentiate toward plasma cells 3 . To determine the effect of romidepsin on BCL6 expression, we analyze the effect of this histone deacetylase inhibitor on several BL cell lines with different BCL6 expression levels (see Supplementary Table S1 ). Romidepsin reduced BCL6 mRNA (not shown) and protein levels ( Fig. 4a ) in a dose and time dependent manner. In DG75, BCL6 downregulation takes place after 24 hours of romidepsin treatment either with 2 nM or 5 nM concentrations. In Raji and Ramos, reduced BCL6 levels were observed upon 48 to 72 hours of treatment. Romidepsin effects on CCND2 (Cyclin D2), a direct target of BCL6 35 , were evaluated. We found a strong increase in the CCND2 mRNA levels in Raji and DG75 in response to romidepsin, and a modest upregulation in Ramos cells ( Fig. 4b) , supporting a functionally important downregulation of BCL6 by romidepsin.
BCL6 downregulation is essential for B-cells to leave the germinal center and to differentiate towards plasma cell. As a consequence of BCL6 downregulation, induction of target genes essential for B-cells to differentiate into plasma cells, such as PRDM1 (BLIMP1), takes place. We analyzed PRDM1 mRNA levels in the B-cell lymphoma www.nature.com/scientificreports www.nature.com/scientificreports/ cell lines upon romidepsin treatment. The gene was upregulated in Raji, DG75 and Ramos cells ( Fig. 4c ). No significant changes were detected in the non-GC Ly03 cell line ( Supplementary Fig. S1 ). B-cells exit from germinal centers and plasma cell differentiation program not only requires changes in BCL6 and PRDM1 expression but also changes in other regulators such as PAX5 and XBP1 3 . We chose the extensively used cell line model Ramos to study the modifications in the expression of these other genes. A clear increase in BLIMP1 protein levels was detected in Ramos cells upon romidepsin treatment ( Fig. 4d ), accompanied by a decrease in PAX5 and XBP1 mRNA expression ( Fig. 4e ). Finally, surface markers were analyzed by flow cytometry in Ramos cells. The induction of plasma cell differentiation was corroborated by the decrease of CD20 (B-cell marker) and the increase of CD138 (plasma cell marker) ( Fig. 4f ).
Altogether these results indicate that romidepsin triggers differentiation towards plasma cell differentiation by inhibiting BCL6 expression and this is independent of apoptosis induced by romidepsin. www.nature.com/scientificreports www.nature.com/scientificreports/ Romidepsin induces BCL6 acetylation. BCL6 regulation is critical for germinal center development.
Acetylation inactivates BCL6 either under physiological conditions or induced by the histone deacetylase inhibitor trichostatin A 20 . Although we have shown that long-term romidepsin treatment downregulates BCL6, we wondered whether romidepsin was able to induce BCL6 acetylation at shorter times. Using Ramos germinal center cells as a model, we assayed BCL6 acetylation after romidepsin treatment. Acetylation was assessed by immunoprecipitation with an antibody against BCL6, followed by western blot employing an antibody widely demonstrated to recognize acetylated lysines in several transcription factors or an antibody against BCL6 ( Fig. 5a ). We found increased BCL6 acetylation (3.9-fold) after 3 hours of romidepsin treatment and this acetylation remains after 6 hours of treatment, although to a lesser extent (2.1-fold) ( Fig. 5a top panel) . Under all conditions there were approximately equal amounts of BCL6 in each immunoprecipitate ( Fig. 5a bottom panel) . These results are similar to those previously reported using a different HDACi 20 , demonstrating that romidepsin induces BCL6 acetylation.
Romidepsin effects on transcription and histone marks at the BCL6 locus. As previously described, BCL6 bound to the BCL6 exon1A represses its own transcription 7, 36, 37 . To investigate if the acetylation of BCL6 induced by romidepsin had consequences for transcription from the BCL6 locus, we used luciferase reporter assay in HEK-293T, a cell line that does not express BCL6 (Fig. 5b ). We prepared a luciferase reporter construct containing the BCL6 binding site in exon1A, designated as BCL6(exon1A)pGL3. This reporter was cotransfected with a BCL6 expression vector (pCDNA-BCL6). Low luciferase activity was detected in cells transfected with pCDNA-BCL6 in the absence of romidepsin due to the BCL6 negative autoregulation. Luciferase activity progressively increased with romidepsin in a dose-dependent manner (Fig. 5b) . Therefore, the negative regulation of BCL6 was counteracted by romidepsin, suggesting that the HDACi is inhibiting BCL6 negative autoregulation by acetylation.
We have previously demonstrated that the chromatin regulator CTCF epigenetically regulates BCL6 by binding to BCL6 exon1A 15 . In addition, we have observed that (at timepoints longer than 24 hours) romidepsin reduces BCL6 expression ( Fig. 4a ). Therefore, we aimed to analyze the CTCF occupancy of the BCL6 exon1A in that context, using ChIP assays in Ramos cells. Results revealed CTCF binding to the BCL6 exon1A in the untreated cells, which strongly diminishes upon treatment with romidepsin ( Fig. 5c ). Finally, we analyzed the effect of romidepsin on the local chromatin structure at exon1A. Ramos cells were treated with romidepsin and ChIP assays using antibodies against modified histones were performed. A reduction in the binding of the active histone mark H3Ac together with an enrichment of the H3K9me3 repressive histone was observed in the BCL6 exon1A when cells were treated with romidepsin ( Fig. 5d ). Together these results indicate that romidepsin protects the BCL6 regulatory region against CTCF binding thus favoring the incorporation of repressive histone marks on BCL6 exon1A.
Collectively our results indicate that, at relatively short time-points, romidepsin inhibition of the BCL6 deacetylation presumably repress BCL6 function as shown by others 20 but increase transcription at the BCL6 locus. At longer time points, romidepsin modifies the local chromatin structure at the BCL6 locus to suppress transcription and consequently BCL6 protein levels, to de-repress transcription of BCL6 target genes.
Romidepsin and JQ1 synergistic effects on proliferation and apoptosis. We next aimed to analyze the effect of combined treatment of the epigenetic drugs romidepsin (HDACi) and JQ1 (BRD4i) in Ramos, a Burkitt lymphoma cell line. Cell viability analysis (WST-1 method) using different concentrations of both compounds were performed to generate combination index (CI) plot ( Supplementary Table S2a ). For further experiments, we choose doses close to the IC 50 values (5 nM romidepsin and 1 µM JQ1) where synergism (CI < 1) was evident ( Fig. 6a ). Growth curve analysis confirmed the synergistic effect on cell proliferation (Fig. 6b ). Annexin V staining ( Fig. 6c ) and cleaved PARP1 (Fig. 6d ) were strongly increased after 48 h with the combination treatment, together with decreased levels of the antiapoptotic protein BCL-xL, indicating significant synergistic effect of romidepsin and JQ1 on apoptotic cell death. Interestingly, the combination treatment dramatically induced the expression of γH2AX (Fig. 6d) , a well-known marker of DNA damage response.
We also analyzed the effects of romidepsin and JQ1 on the cell cycle. Both compounds alone provoked cell cycle arrest and increased the expression of p21 (Fig. 6e) . A further increase in p21 levels was detected after 24 h with the combination treatment. At longer times, this synergistic effect was not evident presumably due to the high proportion of apoptotic cells (Fig. 6c ). The expected decrease in the cyclin A (as a marker of proliferation) and MYC levels was also observed (Fig. 6e ). Finally, we found downregulation of BCL6 expression that was more pronounced upon 48 h of combination treatment while BLIMP1 levels were slightly increased with both romidepsin and JQ1 (Fig. 6f) .
Similar results were obtained in the less sensitive Raji cells from BL as shown by the CI plot ( Fig. 7a , Supplementary Table S2b ), and to a lesser extent in Toledo and DG75 cells ( Supplementary Figs S2 and S3 ). Clear synergistic effects of romidepsin and JQ1 in terms of apoptosis (PARP1 cleavage and γH2AX induction) ( Fig. 7b ), cell cycle arrest (p27 induction, MYC downregulation) and plasmatic differentiation (BCL6 downregulation) ( Fig. 7c) were observed, indicating that the drugs combination could be effective in aggressive B cells lymphoma.
Discussion
Novel strategies for treatment of aggressive lymphomas are needed. DLBCL, one of the most frequent lymphomas in western countries will be refractory to anthracycline conventional treatments in a substantial proportion of cases. BCL6 is a key regulator of normal germinal center B-cells and is expressed in Burkitt lymphoma and some DLBCL. Transcription factors are attractive targets for therapy because they control programs of gene expression 38 . It is likely that the gene expression program controlled by BCL6 has important roles in driving cell cycle progression and proliferation in normal and malignant B-cells 35, 39 in turn suggesting that BCL6 is an attractive target for these types of lymphomas 10, 12, 13 . Inhibition of BCL6 has indeed shown very promising results in preclinical studies 40 www.nature.com/scientificreports www.nature.com/scientificreports/ www.nature.com/scientificreports www.nature.com/scientificreports/ targeting BCL6 might not only be effective on germinal center derived lymphomas but also those ABC-DLBCL cases that express it 41 . However, generation of potent, drug-like inhibitors against BCL6 remains challenging.
We and others, have shown that different epigenetic mechanisms are involved in the modulation of BCL6 expression in the germinal center reaction 14, 15 . Epigenetic modulators are an attractive and effective strategy in a number of malignancies 17 . Among them, more than ten histone deacetylase inhibitors have shown promising results in studies performed in different hematological malignances, including lymphomas 18, 21, 34 . HDACi can produce a variety of effects including induction of apoptosis, cell cycle arrest, induction of differentiation and regulation of immune responses, and these effects are exerted in a cell type specific manner 21, 22, 34, 42 . Some of these effects are generated by the inhibition of activity of HDACs while others might be the consequence of modification of other cellular proteins by acetylation. In this study a number of BL derived cell lines were used to evaluate the effect of romidepsin, a potent HDACi that has been approved for treatment of different types of T cell lymphomas but its role on B cell lymphomas is yet not well known. BL shows high level BCL6 expression and BL cell lines have been used to elucidate many aspects of BCL6 action 35 . We also analyzed the effect of romidepsin in two GC-DLBCL and ABC-DLBCL cell lines, for comparison.
Romidepsin induced apoptosis in metabolically sensitive lymphoma B-cell lines. Several reports have shown a role for the mitochondrial apoptotic pathway in HDACi mediated apoptosis 21, 42 . In some cases BCL2 or BCL-xL, which block the intrinsic apoptotic pathway, are able to overcome the effects of a number of HDACi. Therefore, a differential expression of the pro-apoptotic and the anti-apoptotic BCL2 family members might explain the varying response to romidepsin. In healthy B-cells, BCL2 expression is reduced when B-cells enter the germinal center reaction 43 . Although the basal expression of BCL2 was variable among the cells used in this study, no relationship between BCL2 expression and sensitiveness to romidepsin was observed. This is not surprisingly since romidepsin has been shown to induce apoptosis even in models overexpressing BCL2, but not in BCL-xL models 33 . Although down-regulation of BCL-xL does not imply an immediate death 43 , the reduction in the anti-apoptotic BCL-xL in Ramos and Toledo cells compared to the unchanged levels observed in the DG75 insensitive cell line, imply that BCL-xL might be a good marker for monitoring romidepsin effect in germinal center cells. This is in agreement with previous studies showing how expression of BCL-xL might confer a drug resistance phenotype 44 . Interestingly, BIM was upregulated in both DLBCL (Toledo and Ly03) cells in the presence of romidepsin, which might explain the apoptosis observed in those cell lines, given that BIM plays a critical role in HDACi induced apoptosis 45, 46 . In DG75 and Ramos cells, BIM levels are maintained while MCL1 protein transiently increases upon romidepsin treatment. Since MCL1 is essential for the survival of plasma cells 47 , this transient expression of MCL1 detected in response to romidepsin might be providing a short-term window to allow cells to differentiate into plasma cells and/or die by apoptosis.
It is known that GC B-cells stop proliferating in order to be able to differentiate into plasma cells. Accordingly, cell cycle arrest in G 0 /G 1 phase was observed, together with the increase in p21 and p27, in most of the lymphoma cells analyzed upon exposure to romidepsin. This is in line with previous reports showing, that accumulation of cycling dependent kinase inhibitors is a general effect shared by most of all the histone deacetylase inhibitors, when used on various malignancies 19, 34 .
In this study we have shown that romidepsin (i) induces BCL6 acetylation, which inhibits BCL6 negative autoregulation, and (ii) protects the BCL6 regulatory region against CTCF binding thus favouring the incorporation of repressive histone marks. In agreement, treatment of DLBCLs with other HDACi has been shown to induce hyperacetylation of BCL6, reactivation of repressed target genes and induction of apoptosis 20, 48 . In our study, the romidepsin-mediated downregulation of BCL6 was also associated with plasma cell differentiation, as shown by induction of PRDM1 (BLIMP1) levels and the expression of plasma cell surface marker (CD138). In treated Ramos cells, PAX5 mRNA levels were downregulated, PAX5 being necessary for B-cells to maintain their germinal center identity 49, 50 . However, when we analyzed the expression of XBP1, a gene that acts downstream of PRDM1-BLIMP1, we found no upregulation, suggesting that romidepsin might be triggering a partial plasma cell differentiation program but is not sufficient for terminal plasma cell differentiation. Therefore, as expected the mature plasma cell phenotype was not completely reached because cell lines have limited differentiation capacity. The effects of romidepsin on lymphoma B cells are summarized in Fig. 8 .
Combination of HDACi with drugs targeting different cellular pathways are being used with promising results in a number of tumors including lymphomas 18, 19 . Recently, combination treatments of HDAC and BET inhibitors have been described to have synergistic effects in different cancers [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] . In order to further improve the response of aggressive lymphoma cells, we explored the effects of romidepsin together with the BRD4 inhibitor JQ1. BRD4i inhibits MYC expression, frequently deregulated in hematopoietic malignancies 28, 62 . Strong synergistic effect of romidepsin and JQ1 activating DNA-damage response and apoptotic cell death was found in Ramos cells (from BL) as assessed by γH2AX induction, annexin V binding and PARP1 cleavage. Notably, synergy in apoptosis and plasma cell differentiation was also found in the less sensitive Raji and DG75 (from BL) and Toledo (from GC-DLBCL) cells. In agreement with our results, two recent reports demonstrated synergistic effects of romidepsin and JQ1 in solid tumors 55, 56 . This novel combination therapy can be useful to treat poor prognosis or non-responders low survival lymphoma patients.
fold enrichment was determined as indicated in Methods section. (d) Presence of histone marks at the BCL6 exon1A upon treatment with romidepsin. ChIP analysis with CTCF, H3Ac and H3K9me3 antibodies, showing the presence of these proteins at the exon1A of BCL6. Chromatin was prepared from Ramos cells treated with romidepsin. Relative enrichment was quantified by real-time PCR. The fold enrichment of a particular target sequence was determined as indicated in Methods section. Bottom panel shows typical PCR products after the ChIP assays. The gels were cropped for improved clarity and the full-length gels were included in the Supplementary Information file. www.nature.com/scientificreports www.nature.com/scientificreports/ In conclusion, our findings provide new insights into the molecular mechanisms of romidepsin effect on aggressive lymphomas: cell cycle arrest and induction of plasma differentiation is induced upon exposure to the drug and this effect appear to be related to the inhibition of BCL6 expression and function. Romidepsin also induces a variable apoptotic effect that is significantly increased upon treatment with the BET inhibitor JQ1, which reduces MYC function. Overall our data show a potential role for romidepsin and JQ1 combination for the treatment of aggressive and BCL6 expressing lymphomas. Supplementary Table S1 ) were grown in RPMI-1640 supplemented with 10% or 20% fetal calf serum (Lonza) under standard conditions 15 and confirmed to be mycoplasma free. BCL6, MYC and BCL2 loci status in the studied cell lines were determined by FISH analysis ( Supplementary Table S1 ).
Romidepsin was kindly provided by Celgene (Summit, NJ, USA). (+)-JQ1 was purchase from Cayman Chemical (Ann Arbor, MI, USA). Drugs were diluted in DMSO and stored at −20 °C. To study the effects of the drugs, exponentially growing cells were treated with the different drug concentrations for several time points, depending on the experiment and cell line.
Cell proliferation and viability assays. Cells were treated with different doses of romidepsin and/or JQ1 for up to 96 h. Cell proliferation and cell viability was measured using the Guava ViaCount reagent (Merck Millipore, Darmstadt, Germany) or the NucleoCounter system (Chemometec, Allerod, Denmark). Metabolic activity of cells was measured using the WST-1 method (Roche, Basilea, Switzerland) which allows the quantification of the number of viable cells by the cleavage of tetrazolium salt WST-1 to formazan dye. Romidepsin and JQ1 combination effects were determined using the combination index (CI) values, analyzed by the Chou-Talalay method using CompuSyn Software 63 .
Cell cycle, apoptosis and differentiation analysis. Cell cycle analysis were performed using propidium iodide staining as previously described 64 . Cells were fixed with cold ethanol and resuspended in PBS-citrate Na-BSA containing RNase and propidium iodide. The stained cells were analyzed by flow cytometry (FACSDiva cytometer). Annexin V-PE Apoptosis detection Kit (Immunostep, Salamanca, Spain) was used for the detection of early apoptotic cells. Cells were treated with romidepsin and JQ1 for 24 and 48 h and Annexin V-binding was analyzed by flow cytometry (FACSDiva TM software, BD biosciences, NJ, USA). The cleavage of poly(ADP-ribose) polymerase-1 (PARP1), indicative of apoptosis, was analyze by immunoblot.
Cell surface markers were analyzed in the Hematology Department of Hospital Marqués de Valdecilla to assess cells differentiation. After 72 h of culture in the presence of 5 nM romidepsin, cell surface markers were analyzed by flow cytometry using the BD FACSDiva flow-cytometer following standard procedures 65 . The conjugated antibodies used were: anti-CD20 PE (BD 345793) from BD Biosciences and anti-CD138 FITC (Rafer; Zaragoza, Spain, IQP 153 F).
RNA analysis by Reverse transcription (RT) and polymerase chain reaction (PCR). Total RNA
was isolated by using the Trizol reagent (Invitrogen, Carlsbad, CA, USA). For reverse transcription, first-strand cDNA was synthesized from 1 µg of total RNA using the iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA). Quantitative PCR was performed with a IQTM SyBR Green Supermix kit (Bio-Rad). mRNA expression was normalized to ribosomal protein S14 mRNA levels (primers shown in Supplementary Table S3 ). Results were analyzed by comparative ΔΔCt method and expressed as mean ± SEM of duplicate PCRs from at least two independent experiments. www.nature.com/scientificreports www.nature.com/scientificreports/ Immunoblot and immunoprecipitation assays. Cells were lysed in lysis buffer (1% NP-40, 100 mM NaCl, 20 mM Tris-HCl pH 7.4, 10 mM NaF, 1 mM orthovanadate and protease and phosphatase inhibitors cocktail). Samples were sonicated and subjected to SDS-PAGE and immunoblot as described previously 66 . The antibodies used were: anti-actin (I-19, sc1616), anti-BCL6 (N-3, sc858), anti-PARP1 (H-250, sc7150), anti-CycA (H-432, sc751) from Santa Cruz Biotech. (Santa Cruz, CA, USA); anti-BCL-xL (ab7974) from Abcam (Cambrigde, UK); anti-BCL2 (2876), anti-BIM (C34C5), anti-MCL1 (4572), anti-BLIMP1 (C14A4), anti-GAPDH (14C10), anti-cMYC (9402S), anti-p27 (3686), anti-p21 (2947) from Cell Signalling Tech. (Danvers, MA, USA); Anti-phospho-Histone H2A.X (Ser139) (05-636) from Millipore (Darmstadt, Germany). Blots were developed with secondary antibodies conjugated to IRDye680 or IRDye800 (Li-Cor Biosciences, LiCor, Lincoln, NE, USA) and immunocomplexes were detected with an Odyssey infrared-imaging system (Li-Cor Biosciences). Some blots were revealed with the ECL system (Bio-Rad).
Immunoprecipitations were performed essentially as described 67 . For detection of the endogenous acetylated BCL6, Ramos cells were lysed in lysis buffer (50 mM Tris-HCl, 250 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholic acid, 0.1% SDS) containing 1 μM romidepsin and protease inhibitors cocktail. Protein extracts were immunoprecipitated with 3 μg of a mouse monoclonal antibody against BCL6 (PG-B6P) or unspecific immunoglobulins used as a control (IgGs sc-2025), from Santa Cruz Biotech. Dynabeads-protein G-bound magnetic beads (Invitrogen) were used to capture protein-antibody immunocomplexes. Immunocomplexes were resolved by SDS-PAGE and analyzed by western blot with antibody against acetyl lysine (9441, Cell Signaling). The same filter was then incubated with an anti-BCL6 (N3, sc858) rabbit polyclonal antibody.
Luciferase reporter assays. HEK-293T cells were transiently transfected using polyethilenimine (PEI) transfection reagent (Polysciences Inc., Warrington, PA, USA) as previously described 15 and reporter experiments were performed essentially as described 20 . 0.3 µg of the pGL3-basic vector (Promega) or 0.35 µg of the BCL6(exon1)-pGL3 reporter vector 68 and 0.1 µg of the pRL-null vector (Promega) were cotransfected with pCDNA-BCL6 expression vector 15 . Cells were treated for 12 hours with different concentrations of romidepsin. Luciferase activities were measured 48 hours after transfection using the Dual-Glo Luciferase Reporter System (Promega, Madison, WI, USA) in a Luminometer TD 20/20 Turner Designs. For each determination, luciferase activity was calculated as the Firefly activity normalized by the Renilla activity. Luciferase activity in arbitrary units (a.u.) was shown as the increase in activation relative to the activity of the pGL3 vector alone and the maximum value for each condition was set to 100.
Chromatin immunoprecipitation (ChIP). For ChIP experiments chromatin was prepared from Ramos cells treated with 5 mM romidepsin for 48 h. ChIP assays were performed using the Pierce Magnetic ChIP Kit (Thermo Fisher Scientific, Waltham, MA, USA) following the manufacturer's protocol. Cells were fixed in formaldehyde, lysed, treated with Micrococcal nuclease and sonicated using a Bioruptor UCD-200TM (Diagenode, Liège, Belgium). ChIP was performed using ChIP-Grade Protein A/G Magnetic Beads coupled to different antibodies: anti-CTCF-Ab-1 (07-729) from Millipore, anti-CTCF (ab10571) from Abcam; anti-CTCF (612149) from BD and anti-H3acetylated (06-599) from Millipore; anti-H3K9me3 (ab8898) from Abcam. Real-time PCR of immunoprecipitated DNA was performed in duplicate with equal amounts of specific antibody immunoprecipitated sample, control (beads) and input. Primers used for ChIP assays corresponding to the BCL6 exon 1A (+257) were: 5′-GCACTCCCCCTCTTATGTCA-3′ and 5′-GATTTGGAGGTTCCGGTTC-3′ 15 . The comparative cycle threshold approach was used for the data analysis 15 . The signals were normalized to the inputs and the fold enrichment was calculated relative to the control sample (no-antibody). The values are the mean ± S.E.M. of two to six independent experiments. Normalization of histone marks was based on the ChIP-IT qPCR analysis kit (Active motif North America, Carlsbad, CA, USA).
Statistical analysis.
Results were presented as the mean of two to four determinations with error bars representing the standard error of the mean. The significance of differences was determined by the unpaired Student's t test; a p < 0.05 was considered to be statistically significant.
